Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8485274rdf:typepubmed:Citationlld:pubmed
pubmed-article:8485274lifeskim:mentionsumls-concept:C0025815lld:lifeskim
pubmed-article:8485274lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:8485274lifeskim:mentionsumls-concept:C0037993lld:lifeskim
pubmed-article:8485274lifeskim:mentionsumls-concept:C0021852lld:lifeskim
pubmed-article:8485274lifeskim:mentionsumls-concept:C0023884lld:lifeskim
pubmed-article:8485274lifeskim:mentionsumls-concept:C0021390lld:lifeskim
pubmed-article:8485274lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8485274lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:8485274lifeskim:mentionsumls-concept:C0443172lld:lifeskim
pubmed-article:8485274lifeskim:mentionsumls-concept:C0591833lld:lifeskim
pubmed-article:8485274pubmed:issue2lld:pubmed
pubmed-article:8485274pubmed:dateCreated1993-6-9lld:pubmed
pubmed-article:8485274pubmed:abstractTextThe aim of this study was to evaluate the influence of methylprednisolone (1 mg/kg, i.p.) on inflammatory lesions in the small bowel, liver (pericholangitis) and spleen (lymphofollicular proliferation), in a model of inflammatory bowel disease induced by 2.4-dinitrofluorobenzene in previously sensitized BALB-c mice. As a parameter of corticosteroid anti-inflammatory and immunosuppressive action, we simultaneously investigated its effects on mononuclear cell accumulation within the ileal lamina propria and submucosa during the observed time period (1-30 days). We noted a significant decrease in accumulation of mononuclear cells within the lamina propria (P < 0.001). An effect on mononuclear cell infiltration within the ileal submucosa was also noted but was not statistically significant. In addition, pericholangitis in the liver and lymphofollicular proliferation in the spleen were not observed in the experimental group during treatment with methylprednisolone. The results of this study indicate that the previously described model of intestinal inflammation could be used in further research of present and new therapeutic modalities for inflammatory bowel disease.lld:pubmed
pubmed-article:8485274pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8485274pubmed:languageenglld:pubmed
pubmed-article:8485274pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8485274pubmed:citationSubsetIMlld:pubmed
pubmed-article:8485274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8485274pubmed:statusMEDLINElld:pubmed
pubmed-article:8485274pubmed:monthAprlld:pubmed
pubmed-article:8485274pubmed:issn0269-2813lld:pubmed
pubmed-article:8485274pubmed:authorpubmed-author:Rotkvi?IIlld:pubmed
pubmed-article:8485274pubmed:authorpubmed-author:DuvnjakMMlld:pubmed
pubmed-article:8485274pubmed:authorpubmed-author:Bani?MMlld:pubmed
pubmed-article:8485274pubmed:authorpubmed-author:AnneMMlld:pubmed
pubmed-article:8485274pubmed:authorpubmed-author:Grabarevi?ZZlld:pubmed
pubmed-article:8485274pubmed:authorpubmed-author:MihatovSSlld:pubmed
pubmed-article:8485274pubmed:authorpubmed-author:Brki?TTlld:pubmed
pubmed-article:8485274pubmed:authorpubmed-author:TroskotBBlld:pubmed
pubmed-article:8485274pubmed:issnTypePrintlld:pubmed
pubmed-article:8485274pubmed:volume7lld:pubmed
pubmed-article:8485274pubmed:ownerNLMlld:pubmed
pubmed-article:8485274pubmed:authorsCompleteYlld:pubmed
pubmed-article:8485274pubmed:pagination201-6lld:pubmed
pubmed-article:8485274pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:8485274pubmed:meshHeadingpubmed-meshheading:8485274-...lld:pubmed
pubmed-article:8485274pubmed:meshHeadingpubmed-meshheading:8485274-...lld:pubmed
pubmed-article:8485274pubmed:meshHeadingpubmed-meshheading:8485274-...lld:pubmed
pubmed-article:8485274pubmed:meshHeadingpubmed-meshheading:8485274-...lld:pubmed
pubmed-article:8485274pubmed:meshHeadingpubmed-meshheading:8485274-...lld:pubmed
pubmed-article:8485274pubmed:meshHeadingpubmed-meshheading:8485274-...lld:pubmed
pubmed-article:8485274pubmed:meshHeadingpubmed-meshheading:8485274-...lld:pubmed
pubmed-article:8485274pubmed:meshHeadingpubmed-meshheading:8485274-...lld:pubmed
pubmed-article:8485274pubmed:meshHeadingpubmed-meshheading:8485274-...lld:pubmed
pubmed-article:8485274pubmed:meshHeadingpubmed-meshheading:8485274-...lld:pubmed
pubmed-article:8485274pubmed:meshHeadingpubmed-meshheading:8485274-...lld:pubmed
pubmed-article:8485274pubmed:meshHeadingpubmed-meshheading:8485274-...lld:pubmed
pubmed-article:8485274pubmed:year1993lld:pubmed
pubmed-article:8485274pubmed:articleTitleEffect of methylprednisolone on small bowel, spleen and liver changes in a murine model of inflammatory bowel disease.lld:pubmed
pubmed-article:8485274pubmed:affiliationUniversity Hospital Sestre Milosrdnice, Zagreb Department of Gastroenterology, Republic of Croatia.lld:pubmed
pubmed-article:8485274pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8485274lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8485274lld:pubmed